Flt3 ligand fusion proteins and methods of use

Abstract

The invention provides an effectorless immunoglobulin Fc protein, fusions of the effectorless Fc protein to a Flt3 ligand, and methods of using the same.

1 .- 35 . (canceled) 
     
     
         36 . An effectorless Fc protein, comprising an amino acid sequence which is at least 95%, 96%, 97%. 98%, or 99% identical to residues SEQ ID NO: 13, wherein residues 13-17 of SEQ ID NO: 13 comprise the amino acid sequence PVAGP (SEQ ID NO 20) or residue 76 of SEQ ID NO 13 is a glycine. 
     
     
         37 . The effectorless Fc protein of  claim 36 , wherein residues 13-17 of SEQ ID NO: 13 comprise the amino acid sequence PVAGP (SEQ ID NO:20) and residue 76 of SEQ ID NO: 13 is a glycine. 
     
     
         38 . The effectorless Fc protein of  claim 37 , which comprises an amino acid sequence identical to SEQ ID NO: 13. 
     
     
         39 . An effectorless Fc protein which comprises an amino acid sequence identical to SEQ ID NO: 2, 4, 5, 6, 13, or 15. 
     
     
         40 . The effectorless Fc protein according to  claim 36 , wherein the Fc protein is attenuated relative to a wildtype IgG1 Fc region which comprises SEQ ID NO: 12. 
     
     
         41 . An antibody which comprises the effectorless Fc protein of  claim 36 . 
     
     
         42 . The antibody of  claim 41 , which comprises a heavy chain variable domain and a light chain variable domain 
     
     
         43 . The antibody of  claim 41 , wherein the antibody is a monoclonal antibody. 
     
     
         44 . The antibody of  claim 41 , wherein the antibody is a human antibody, a humanized antibody, or a chimeric antibody. 
     
     
         45 . The antibody of  claim 41 , wherein the antibody is a bispecific or multispecific antibody